We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Liver Involvement in White Patients With Sickle-cell Disease

Piera Samperi, MD; Carmela Consalvo, MD; Vincenzo Romano, MD; Salvatore Gelardi, MD; Domenico Di Bella, MD; Gino Schilirò, MD
Arch Pediatr Adolesc Med. 1996;150(11):1177-1180. doi:10.1001/archpedi.1996.02170360067011.
Text Size: A A A
Published online


Background:  Liver involvement and cholelithiasis are common complications of sickle-cell disease. The incidence of clinically evident hepatic damage reported in the literature for black people varies from 15% to 30%, while no data are reported for white people.

Objective:  To evaluate the liver involvement in 40 patients with homozygous sickle cell anemia (the βsβs form of sickle-cell disease) and 102 patients with doubleheterozygous hemoglobin S and β-thalassemia (65 with the βsβ0th and 37 with the βsβ+th form of sickle-cell disease).

Setting:  The Department of Pediatric Hematology and Oncology, University of Catania, Catania, Italy.

Patients:  Outpatients with sickle-cell disease.

Results:  We found that, in our patients, liver disease seems to be clinically irrelevant: only 2 of the 142 patients examined had notable alterations in hepatic function. Cholelithiasis was found in 42.1% of the subjects with the βsβs form of sickle-cell disease and in 26.8% of the subjects with the βsβth form. Age-related analysis revealed a greater incidence of cholelithiasis during the first years of life in the patients with the βsβs form of the disease than in patients with the βsβth form.

Conclusion:  Our data showed that liver involvement in sickle-cell disease is clinically irrelevant, reflecting the fact that the clinical expression of sickle-cell disease in Sicilian patients is moderate.Arch Pediatr Adolesc Med. 1996;150:1177-1180


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.